Shield Therapeutics plc (LON:STX – Get Free Report) shares were down 10.3% during trading on Thursday . The stock traded as low as GBX 3.95 ($0.05) and last traded at GBX 3.99 ($0.05). Approximately 3,463,371 shares were traded during trading, a decline of 32% from the average daily volume of 5,071,751 shares. The stock had previously closed at GBX 4.45 ($0.06).
Shield Therapeutics Price Performance
The stock has a market cap of £34.80 million, a P/E ratio of -111.25 and a beta of 1.42. The business has a 50-day simple moving average of GBX 3.23 and a 200 day simple moving average of GBX 2.37. The company has a current ratio of 2.28, a quick ratio of 2.16 and a debt-to-equity ratio of 134.67.
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
See Also
- Five stocks we like better than Shield Therapeutics
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- How Can Investors Benefit From After-Hours Trading
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
